mash wegovy - Search News

Order byBest matchMost fresh

Wegovy, FDA and Novo

Novo's Wegovy picks up 3rd indication with key FDA approval in the liver disease MASH

With a new endorsement from the FDA, Novo Nordisk’s Wegovy has picked up its third indication and become the second drug approved in a severe form of fatty liver disease. | The FDA has signed off on an accelerated approval for Novo Nordisk's Wegovy to treat certain adults with metabolic-associated steatohepatitis.

BioPharma Dive · 21h

Novo’s Wegovy becomes first GLP-1 drug approved for MASH

Managed Healthcare Executive · 22h

FDA Grants Accelerated Approval of Wegovy to Treat Liver Disease

· 8h

Novo Nordisk (NVO) Receives FDA Approval for Wegovy

On August 15, Novo Nordisk (NYSE:NVO) announced that the FDA had approved the use of its new drug Wegovy to treat adults with noncirrhotic metabolic dysfunction-associated steatohepatitis.

· 1d

Novo Nordisk's Wegovy Snags Conditional FDA Nod For Fatty Liver Disease

· 23h

Madrigal stock falls after Novo Nordisk’s Wegovy wins FDA approval for MASH

Medscape1d

Wegovy Approved for MASH With Fibrosis, No Cirrhosis

Wegovy is now approved by the FDA to treat metabolic-associated steatohepatitis in adults with moderate-to-advanced fibrosis but without cirrhosis.

Investor's Business Daily on MSN15h

Novo Nordisk Rallied On Wegovy's Newest Approval. But This Rival Rallied More.

Novo Nordisk stock jumped Monday after the FDA approved the company's obesity drug, Wegovy, as a treatment for MASH.

Healio18h

FDA approves Wegovy for certain adults with noncirrhotic MASH

The FDA has approved Wegovy for the treatment of adults with noncirrhotic metabolic dysfunction-associated steatohepatitis with moderate to advanced liver fibrosis.Semaglutide 2.4 mg injection (Wegovy,

BioSpace22h

Novo Wins MASH Approval for Wegovy

The label expansion could help Novo Nordisk “help shift the momentum” for Wegovy, after a difficult start to 2025, according to analysts at BMO Capital Markets.

MPR18h

Wegovy Approved for Noncirrhotic MASH With Moderate, Advanced Liver Fibrosis

The approval was based on Part 1 (72 week data) of the randomized, double-blind, placebo-controlled phase 3 ESSENCE trial.

GlobalData on MSN1d

Wegovy becomes first GLP-1RA to gain FDA MASH approval

The drug received accelerated approval for use in patients with metabolic dysfunction-associated steatohepatitis (MASH).